PLoS ONE (Jan 2013)

RBP2 induces epithelial-mesenchymal transition in non-small cell lung cancer.

  • Shikun Wang,
  • Yang Wang,
  • Haijian Wu,
  • Likuan Hu

DOI
https://doi.org/10.1371/journal.pone.0084735
Journal volume & issue
Vol. 8, no. 12
p. e84735

Abstract

Read online

RBP2 has been found to actively participate in cancer progression. It inhibits the senescence of cancer cells, mediates cancer cell proliferation and promotes cancer metastasis. It is also essential to drug tolerance. However, the effects of RBP2 on epithelial-mesenchymal transition are still unknown. In this study, we analyzed the effects of RBP2 on epithelial-mesenchymal transition in non-small cell lung cancer. The results showed that RBP2 down-regulated the expression of E-cadherin by inhibiting the promoter activity of E-cadherin and up-regulated the expression of N-cadherin and snail via the activation of Akt signaling, and the overexpression of RBP2 induced epithelial-mesenchymal transition in non-small cell lung cancer cells. Our study further indicated that RBP2 may be a potential target for anti-lung cancer therapy.